| Product Unit Size | Cost | Quantity | Stock |
|---|
Bleomycin A5 is an anticancer chemotherapeutic that binds DNA and induces DNA cleavage and strand breaks; it is highly toxic. Bleomycin is clinically used to treat lymphomas, squamous cell carcinomas, and testicular cancer. Additionally, this compound induces apoptosis, alters cell cycle regulation, inhibits proliferation, and decreases tumor size in cellular and animal models of hemangioma. Bleomycin may also inhibit thioredoxin reductase.
| Cas No. | 55658-47-4 |
|---|---|
| Purity | ≥90% |
| Formula | C57H89N19O21S2 • HCl |
| Formula Wt. | 1477.02 |
| IUPAC Name | [2-[2-[2-[[6-amino-2-[3-amino-1-[(2, 3-diamino-3-oxopropyl)amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl] amino]-3-[[5-[[1-[2-[4-[4-[3-(4-aminobutylamino)propylcarbamoyl]-1, 3-thiazol-2-yl]-1, 3-thiazol-2-yl]ethylamino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-hydroxy-4- methyl-5-oxopentan-2-yl]amino]-1-(1H-imidazol-5-yl)-3-oxopropoxy]-4, 5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]oxy-3, 5-dihydroxy-6-(hydroxymethyl)oxan-4-yl] carbamate;hydrochloride InChI: InChI=1S/C57H89N19O21S2.ClH/c1-22-35(73-48(76-46(22)61)27(14-33(60)80) 68-15-26(59)47(62)86)52(90)75-37(43(28-16-65-21-69-28)95-56-45(41(84)39 (82)31(17-77)94-56)96-55-42(85)44(97-57(63)92)40(83)32(18-78)93-55)53 (91)70-24(3)38(81)23(2)49(87)74-36(25(4)79)51(89)67-13-8-34-71-30(20-98- 34)54-72-29(19-99-54)50(88)66-12-7-11-64-10-6-5-9-58;/h16,19-21,23-27, 31-32,36-45,55-56,64,68,77-79,81-85H,5-15,17-18,58-59H2,1-4H3,(H2,60, 80)(H2,62,86)(H2,63,92)(H,65,69)(H,66,88)(H,67,89)(H,70,91)(H,74,87)(H, 75,90)(H2,61,73,76);1H |
| Synonym | Pingyangmycin hydrochloride |
| Solubility | Freely soluble in water, slightly soluble in ethanol |
| Appearance | White Crystal Powder |
| Store Temp | 4°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Li P, Li DF, Guo ZT, et al. Therapeutic mechanism of bleomycin A5 on infancy hemangioma: an experimental study. Zhonghua Kou Qiang Yi Xue Za Zhi. 2013 Jan;48(1):18-22. PMID: 23534516.
Yang Y, Sun M, Ma Q, et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg. 2011 Jan;53(1):150-5. PMID: 20843632.
Liu Y, Wu F, Zou G. Electrophoresis mobility shift assay and biosensor used in studying the interaction between bleomycin A5 and DNA. Anal Chim Acta. 2007 Sep 19;599(2):310-4. PMID: 17870295.
Vorobjev PE, Smith JB, Pyshnaya IA, et al. Site-specific cleavage of RNA and DNA by complementary DNA--bleomycin A5 conjugates. Bioconjug Chem. 2003 Nov-Dec;14(6):1307-13. PMID: 14624648.